New law protects subsidies for obesity drugs when transitioning to Medicare

The House Ways and Means Committee voted 36-4 in favor of an amended bill on Thursday.

Public subsidies for obesity drugs through Medicare have been banned since the 2000s.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles

Receive our daily newsletters

Access our app

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

Leo Pharma's HR director leaves after less than a year – interim replacement found

The reason is due to unforeseen family circumstances.

Leo Pharma gets green light from FDA for Adbry autoinjector

VP of Leo Pharma makes the switch to Fujifilm Diosynth Biotechnologies

For subscribers

”I don’t think this is a strong enough signal to take the medication away from patients," says one neuro-opthamologist who wrote an accompanying paper for the study. | Foto: Hollie Adams/Reuters/Ritzau Scanpix

Pharma & biotech

Study links Novo Nordisk blockbuster to rare vision loss

Pharma & biotech

Novo Nordisk highlights several limitations of study linking Ozempic and Wegovy to sight loss

For subscribers

Pharma & biotech

Analyst calls for calm after study links Novo Nordisk's bestsellers to sight loss

For subscribers

Foto: Cole Burston/Reuters/Ritzau Scanpix

Pharma & biotech

Sanofi gets Dupixent approved for the treatment of COPD in the EU

Lars Nørby Johansen has influenced several of the largest companies in Denmark, such as Falck and Dong, and today, in addition to the William Demant Foundation, he is also chairman of the board of Copenhagen Airport and Montana Furniture. | Foto: Lars Krabbe

Hearing health

William Demant Foundation chairman distances himself from fired executive- but will still put him on boards

For subscribers

Novo Nordisk on Biden's price criticism: A complex problem abused for political purposes

Both Novo Nordisk and rival Eli Lilly were the targets of an op-ed written by US President Joe Biden and Senator Bernie Sanders.

For subscribers

Major investor on ALK: Pipeline is lacking

ALK needs to find new sources of revenue if it is to maintain growth of more than 10%, according to the major investor.

For subscribers

Studies have found that the new drug slows down the progression of Alzheimer's. | Foto: Mike Blake/Reuters/Ritzau Scanpix

Eli Lilly gets Alzheimer's drug approved in the US

Kisunla is a treatment for the early symptoms of the degenerative disease.

Novo Nordisk bombards US TV viewers with Wegovy commercials

The total cost of Novo Nordisk’s commercial slot for Wegovy amounted to USD 42m in June.

For subscribers

Joe Biden demands lower prices for Wegovy and Ozempic

This is not the first time Joe Biden has criticized the high price of medicine in the US.

For subscribers

Henrik Blou, CEO, Gubra | Foto: Thomas Muus / Gubra / Pr

Gubra crowned Danish biotech firm of the year: "We have focused on the exciting research"

A hybrid business model and stable ownership are ingredients in Gubra’s recipe for success, says CEO Henrik Blou, who has a special niche carved out for the firm within obesity.

For subscribers

Leo Pharma's HR director leaves after less than a year – interim replacement found

The reason is due to unforeseen family circumstances.

For subscribers

Pharma & biotech

Novo Nordisk implements hiring freeze in certain departments

Since 2021, Novo Nordisk has increased its number of employees by 20,000 to total 66,000.

For subscribers

Pharma & biotech

Novo Nordisk on Biden's price criticism: A complex problem abused for political purposes

Both Novo Nordisk and rival Eli Lilly were the targets of an op-ed written by US President Joe Biden and Senator Bernie Sanders.

For subscribers

Pharma & biotech

Study links Novo Nordisk blockbuster to rare vision loss

A larger study is needed to confirm or refute the findings, say analysts. Corrected.

Pharma & biotech

Novo Nordisk bombards US TV viewers with Wegovy commercials

The total cost of Novo Nordisk’s commercial slot for Wegovy amounted to USD 42m in June.

For subscribers

Pharma & biotech

Novo Nordisk highlights several limitations of study linking Ozempic and Wegovy to sight loss

The study is not designed to show a causal relationship with the eye condition, the pharmaceutical company points out.

For subscribers

Jobs

Laboratory Technician

International Marketing Manager/Director

ESG Officer

Material Scientist and Coordinator

Head of Quality Assurance

QA/RA Specialist, Patient Handling Division

Senior Director R&D Project Management Office (PMO)

Principal Research Scientist within Biophysical characterisation and pre-formulation

Lead Regulatory Professional – Combination Products

Principal Bioinformatic Scientist, Antibody Technology

Governmental Public Affairs & Communications Head

Senior Laboratory Technician (Laborant) – Biophysical Protein Characterization

Production chemist

Toxicologist, Non-clinical Development

QA Manager GMP

Global Head of Rewards

Skilled Process Specialist for managing logistic and production processes in SAP

Quality Engineer for Production

Investor Relations Manager

Principal Quality Assurance Professional – Combination Products

Healthcare Compliance Senior Specialist (Associated Director), Ascendis Pharma

See all jobs

New law protects subsidies for obesity drugs when transitioning to Medicare

Read the whole article

With your free trial you get:

Get full access for you and your coworkers

Share article

Related articles

Novo Nordisk CEO to testify before senate committee in September

Novo on US senate subpoena vote: "We have repeatedly told them that Lars Fruergaard would be happy to testify"

Eli Lilly sees big potential in severe obesity candidates

Sign up for our newsletter

Front page now

Leo Pharma's HR director leaves after less than a year – interim replacement found

Study links Novo Nordisk blockbuster to rare vision loss

Novo Nordisk highlights several limitations of study linking Ozempic and Wegovy to sight loss

Analyst calls for calm after study links Novo Nordisk's bestsellers to sight loss

Sanofi gets Dupixent approved for the treatment of COPD in the EU

William Demant Foundation chairman distances himself from fired executive- but will still put him on boards

Novo Nordisk on Biden's price criticism: A complex problem abused for political purposes

Major investor on ALK: Pipeline is lacking

Eli Lilly gets Alzheimer's drug approved in the US

Novo Nordisk bombards US TV viewers with Wegovy commercials

Joe Biden demands lower prices for Wegovy and Ozempic

Gubra crowned Danish biotech firm of the year: "We have focused on the exciting research"

Further reading

Leo Pharma's HR director leaves after less than a year – interim replacement found

Novo Nordisk implements hiring freeze in certain departments

Novo Nordisk on Biden's price criticism: A complex problem abused for political purposes

Study links Novo Nordisk blockbuster to rare vision loss

Novo Nordisk bombards US TV viewers with Wegovy commercials

Novo Nordisk highlights several limitations of study linking Ozempic and Wegovy to sight loss

Jobs